MedSci学院:心血管积分与量表

2015-09-10 MedSci MedSci原创

患者自我报告的临床结果是评价患者愈后的一个重要指标,常见的有评分和量表。量表相对评分来说,更为复杂,但量表评价的维度更全面,有利于更全面评价患者的生活质量各个因素,因此,价值也很高。 MedSci学院开始“心血管积分与量表”,主要介绍心血管领域量表的内容及功能,旨在抛砖引玉,让大家了解量表的复杂性,以及应用特点,给大家在各个学科的实践和研究中得到启示。该课程分4个小节: 1、心

患者自我报告的临床结果是评价患者愈后的一个重要指标,常见的有评分和量表。量表相对评分来说,更为复杂,但量表评价的维度更全面,有利于更全面评价患者的生活质量各个因素,因此,价值也很高。

 
MedSci学院开设“心血管积分与量表”,主要介绍心血管领域量表的内容及功能,旨在抛砖引玉,让大家了解量表的复杂性,以及应用特点,给大家在各个学科的实践和研究中得到启示。该课程分4个小节:
 
1、心血管积分与量表---前言
http://edu.medsci.cn/course_info/medsci-xin-xue-guan-ji-feng-yu-liang-biao.html

4、心血管积分与量表---小结
http://edu.medsci.cn/course_info/medsci-xin-xue-guan-ji-fen-yu-liang-biao-xiao-jie.html
 
临床更多评分工具,可查阅http://tools.medsci.cn
 

下载MedSci医学APP,手机观看课程更快捷!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=996846, encodeId=f80d9968466d, content=好用, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c175540100, createdName=ms4000001832228962, createdTime=Tue Jul 06 15:57:31 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36830, encodeId=a95936830e6, content=学习啦!, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3f21649461, createdName=1ddc3cc3m12(暂无匿称), createdTime=Sat Sep 12 09:41:00 CST 2015, time=2015-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606606, encodeId=16f71606606d2, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Sep 12 07:32:00 CST 2015, time=2015-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36811, encodeId=2c773681194, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3f21649461, createdName=1ddc3cc3m12(暂无匿称), createdTime=Fri Sep 11 16:08:00 CST 2015, time=2015-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36810, encodeId=1ab33681065, content=谢谢分享!学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3f21649461, createdName=1ddc3cc3m12(暂无匿称), createdTime=Fri Sep 11 16:07:00 CST 2015, time=2015-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36699, encodeId=3665366996b, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCEEr4dM45RatXXGAkFCicnNYiasFiaRicicO1YWsIeTFOhgapauqib8Z8TChNB3ttVC5RqNHptDvAxA72Q/0, createdBy=a82a1611288, createdName=yydlt, createdTime=Thu Sep 10 22:10:00 CST 2015, time=2015-09-10, status=1, ipAttribution=)]
    2021-07-06 ms4000001832228962

    好用

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=996846, encodeId=f80d9968466d, content=好用, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c175540100, createdName=ms4000001832228962, createdTime=Tue Jul 06 15:57:31 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36830, encodeId=a95936830e6, content=学习啦!, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3f21649461, createdName=1ddc3cc3m12(暂无匿称), createdTime=Sat Sep 12 09:41:00 CST 2015, time=2015-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606606, encodeId=16f71606606d2, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Sep 12 07:32:00 CST 2015, time=2015-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36811, encodeId=2c773681194, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3f21649461, createdName=1ddc3cc3m12(暂无匿称), createdTime=Fri Sep 11 16:08:00 CST 2015, time=2015-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36810, encodeId=1ab33681065, content=谢谢分享!学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3f21649461, createdName=1ddc3cc3m12(暂无匿称), createdTime=Fri Sep 11 16:07:00 CST 2015, time=2015-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36699, encodeId=3665366996b, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCEEr4dM45RatXXGAkFCicnNYiasFiaRicicO1YWsIeTFOhgapauqib8Z8TChNB3ttVC5RqNHptDvAxA72Q/0, createdBy=a82a1611288, createdName=yydlt, createdTime=Thu Sep 10 22:10:00 CST 2015, time=2015-09-10, status=1, ipAttribution=)]
    2015-09-12 1ddc3cc3m12(暂无匿称)

    学习啦!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=996846, encodeId=f80d9968466d, content=好用, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c175540100, createdName=ms4000001832228962, createdTime=Tue Jul 06 15:57:31 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36830, encodeId=a95936830e6, content=学习啦!, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3f21649461, createdName=1ddc3cc3m12(暂无匿称), createdTime=Sat Sep 12 09:41:00 CST 2015, time=2015-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606606, encodeId=16f71606606d2, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Sep 12 07:32:00 CST 2015, time=2015-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36811, encodeId=2c773681194, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3f21649461, createdName=1ddc3cc3m12(暂无匿称), createdTime=Fri Sep 11 16:08:00 CST 2015, time=2015-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36810, encodeId=1ab33681065, content=谢谢分享!学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3f21649461, createdName=1ddc3cc3m12(暂无匿称), createdTime=Fri Sep 11 16:07:00 CST 2015, time=2015-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36699, encodeId=3665366996b, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCEEr4dM45RatXXGAkFCicnNYiasFiaRicicO1YWsIeTFOhgapauqib8Z8TChNB3ttVC5RqNHptDvAxA72Q/0, createdBy=a82a1611288, createdName=yydlt, createdTime=Thu Sep 10 22:10:00 CST 2015, time=2015-09-10, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=996846, encodeId=f80d9968466d, content=好用, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c175540100, createdName=ms4000001832228962, createdTime=Tue Jul 06 15:57:31 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36830, encodeId=a95936830e6, content=学习啦!, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3f21649461, createdName=1ddc3cc3m12(暂无匿称), createdTime=Sat Sep 12 09:41:00 CST 2015, time=2015-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606606, encodeId=16f71606606d2, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Sep 12 07:32:00 CST 2015, time=2015-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36811, encodeId=2c773681194, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3f21649461, createdName=1ddc3cc3m12(暂无匿称), createdTime=Fri Sep 11 16:08:00 CST 2015, time=2015-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36810, encodeId=1ab33681065, content=谢谢分享!学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3f21649461, createdName=1ddc3cc3m12(暂无匿称), createdTime=Fri Sep 11 16:07:00 CST 2015, time=2015-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36699, encodeId=3665366996b, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCEEr4dM45RatXXGAkFCicnNYiasFiaRicicO1YWsIeTFOhgapauqib8Z8TChNB3ttVC5RqNHptDvAxA72Q/0, createdBy=a82a1611288, createdName=yydlt, createdTime=Thu Sep 10 22:10:00 CST 2015, time=2015-09-10, status=1, ipAttribution=)]
    2015-09-11 1ddc3cc3m12(暂无匿称)

    谢谢分享!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=996846, encodeId=f80d9968466d, content=好用, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c175540100, createdName=ms4000001832228962, createdTime=Tue Jul 06 15:57:31 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36830, encodeId=a95936830e6, content=学习啦!, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3f21649461, createdName=1ddc3cc3m12(暂无匿称), createdTime=Sat Sep 12 09:41:00 CST 2015, time=2015-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606606, encodeId=16f71606606d2, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Sep 12 07:32:00 CST 2015, time=2015-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36811, encodeId=2c773681194, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3f21649461, createdName=1ddc3cc3m12(暂无匿称), createdTime=Fri Sep 11 16:08:00 CST 2015, time=2015-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36810, encodeId=1ab33681065, content=谢谢分享!学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3f21649461, createdName=1ddc3cc3m12(暂无匿称), createdTime=Fri Sep 11 16:07:00 CST 2015, time=2015-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36699, encodeId=3665366996b, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCEEr4dM45RatXXGAkFCicnNYiasFiaRicicO1YWsIeTFOhgapauqib8Z8TChNB3ttVC5RqNHptDvAxA72Q/0, createdBy=a82a1611288, createdName=yydlt, createdTime=Thu Sep 10 22:10:00 CST 2015, time=2015-09-10, status=1, ipAttribution=)]
    2015-09-11 1ddc3cc3m12(暂无匿称)

    谢谢分享!学习了!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=996846, encodeId=f80d9968466d, content=好用, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c175540100, createdName=ms4000001832228962, createdTime=Tue Jul 06 15:57:31 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36830, encodeId=a95936830e6, content=学习啦!, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3f21649461, createdName=1ddc3cc3m12(暂无匿称), createdTime=Sat Sep 12 09:41:00 CST 2015, time=2015-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606606, encodeId=16f71606606d2, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Sep 12 07:32:00 CST 2015, time=2015-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36811, encodeId=2c773681194, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3f21649461, createdName=1ddc3cc3m12(暂无匿称), createdTime=Fri Sep 11 16:08:00 CST 2015, time=2015-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36810, encodeId=1ab33681065, content=谢谢分享!学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3f21649461, createdName=1ddc3cc3m12(暂无匿称), createdTime=Fri Sep 11 16:07:00 CST 2015, time=2015-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36699, encodeId=3665366996b, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCEEr4dM45RatXXGAkFCicnNYiasFiaRicicO1YWsIeTFOhgapauqib8Z8TChNB3ttVC5RqNHptDvAxA72Q/0, createdBy=a82a1611288, createdName=yydlt, createdTime=Thu Sep 10 22:10:00 CST 2015, time=2015-09-10, status=1, ipAttribution=)]
    2015-09-10 yydlt

    不错!

    0

相关资讯

ESC 2015:年轻糖尿病女性心脏病的发病风险可高达6倍

年轻糖尿病女性心脏病的发病风险可高达6倍研究发现年轻糖尿病女性可有高达6倍的心脏病发病风险,研究共纳入了7000名45岁及以下的女性。研究还指出,论心脏病的发病风险,吸烟较老龄大一些。心血管疾病主要影响老年人群,但是近些年来,年轻人(不分性别)的发病率也越来越高。据WHO统计,心血管疾病所致的女性死亡占女性总死亡的52%,而且这个比例正不断加大。心脏病发作患者中1%为年轻女性。与无MI病史的女性相

大陆心血管论文被引TOP 100出炉:陈绍良以703次称冠

2004-2015年,在中国大陆被引频次100名之内的文章中,来自北京的论文数量最多,共34篇;上海发表的论文平均被引次数最高,平均每篇被引105.6次。陈绍良一人就有3篇高引用次数的论文,平均引用次数为273次,他一项有关干细胞的研究被引频率高达703次。TOP 100文章中,一半为基础研究,43篇为临床研究,6篇为Meta分析,1篇综述。43项临床研究中,13项为随机临床研究,其余30项为观察

Ann Intern Med:强直性脊柱炎可增加患者心血管和脑血管疾病的死亡率

Ann Intern Med:强直性脊柱炎或可增加患者心血管和脑血管疾病的死亡率近日有研究表明,强直性脊柱炎可增加心血管或脑血管疾病死亡率的风险,该研究成果于2015年8月11日在线发表于Ann Intern Med。强直性脊柱炎(AS)是一种主要侵犯于年轻人脊柱的慢性炎症性关节炎,既往研究表明强直性脊柱炎可增加心血管及脑血管疾病死亡率。本研究以人群为基础,采用回顾性队列研究分析研究加拿大的健康管

AHA声明:手机App应用可有助于心血管健康的管理

尽管我们目前可以获得诸如智能手机里各种App应用及运动传感程序等数不胜数的健康工具来管理心血管风险因素,但这些工具的效果却并未得到证实。尽管如此,临床医生仍鼓励患者使用这些工具来管理自身的心血管风险。因此,亟需研究以探究这些工具的有效性。8月13日,针对此问题美国心脏学会(AHA)在circulation上发表了科学声明。该声明由Dr Lora Burke及其同事所制定,主要分析了移动端健康工具对

依折麦布药物或降低急性冠脉综合征患者的发病率!

依折麦布可降低糖尿病患者和急性冠脉综合征患者的心血管疾病的发病率,根据布莱根妇女医院的心内科医生Robert Giugliano博士进行的IMPROVE-IT试验指出,依折麦布比单独使用他汀类药物降低低密度脂蛋白胆固醇的效果更好,从而可降低糖尿病患者心脑血管事件发生的风险。“急性冠脉综合征,包括心肌梗塞和不稳定型心绞痛(心梗先兆),是世界各地民众死亡和心功能不全的主要原因,”Robert Giug

Lancet Dia & Endo:服用Albiglutide对心血管安全性的研究

Albiglutide是胰高血糖素样肽-1受体激动剂,是一类新的用于治疗2型糖尿病的药物。研究人员进行了一项前瞻性研究的荟萃分析,由美国食品和药物管理局建议糖尿病新疗法的评价,评估albiglutide心血管安全性。研究人员对8个3期临床试验,一个2b期试验做了荟萃分析,患者被随机分配接受albiglutide,安慰剂或活性对照药物(格列美脲,甘精胰岛素,赖脯胰岛素,利拉鲁肽,吡格列酮,或西格列汀